Rosen Law Firm has initiated a class action lawsuit against REGENXBIO, Inc., targeting investors who acquired company securities during a nearly four-year window from February 9, 2022, through January 27, 2026. The litigation centers on allegations that the company made materially false and misleading statements regarding the efficacy and safety profile of RGX-111, an experimental gene therapy treatment for Hurler syndrome, while simultaneously withholding adverse information pertaining to clinical trial results.
According to the complaint, REGENXBIO failed to disclose significant negative developments related to the trial study, potentially affecting the investment decisions of securities holders during the class period. The lawsuit seeks to recover damages on behalf of affected investors who claim to have suffered losses based on the company's allegedly inaccurate public statements and omissions of material facts.
Investors who purchased REGENXBIO securities during the specified timeframe are urged to contact legal counsel promptly, as the deadline to serve as lead plaintiff in the class action is April 14, 2026. Eligible parties should review the case details and consult with securities attorneys to understand their potential rights and remedies under applicable securities laws.